Novartis AG (VTX:NOVN) received a CHF 80 price target from analysts at Goldman Sachs Group, Inc. (The) in a note issued to investors on Tuesday. The brokerage presently has a “neutral” rating on the stock.

NOVN has been the subject of several other research reports. Deutsche Bank AG set a CHF 81 price target on Novartis AG and gave the stock a “neutral” rating in a research report on Wednesday, July 19th. J P Morgan Chase & Co set a CHF 75 price target on Novartis AG and gave the stock a “neutral” rating in a research report on Wednesday, July 19th. S&P Global set a CHF 82 price target on Novartis AG and gave the stock a “neutral” rating in a research report on Tuesday, July 18th. Sanford C. Bernstein set a CHF 94 price target on Novartis AG and gave the stock a “buy” rating in a research report on Tuesday, July 18th. Finally, UBS AG set a CHF 76 price target on Novartis AG and gave the stock a “neutral” rating in a research report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of CHF 85.37.

Shares of Novartis AG (NOVN) traded down 0.47% during mid-day trading on Tuesday, reaching CHK 84.10. 3,177,121 shares of the company’s stock were exchanged. The firm has a market capitalization of CHK 197.04 billion and a P/E ratio of 30.70. The stock has a 50-day moving average of CHK 82.36 and a 200 day moving average of CHK 79.72. Novartis AG has a one year low of CHK 67.40 and a one year high of CHK 84.65.

TRADEMARK VIOLATION NOTICE: “Goldman Sachs Group, Inc. (The) Analysts Give Novartis AG (NOVN) a CHF 80 Price Target” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/17/goldman-sachs-group-inc-the-analysts-give-novartis-ag-novn-a-chf-80-price-target.html.

About Novartis AG

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.